Search

Vincent A Pollack

from Gales Ferry, CT
Deceased
Get Report
Also known as:
Vince Pollack
Phone and address:
55 Vinegar Hill Rd, Gales Ferry, CT 06335
(860) 464-9347
Related to:
John J Foley, 76Joseph E Pollack, 41
Connected to:
Alice Pollack, 52Alyssa Pollack, 46Anita M Pollack, 83Ann M Pollack, 57Avi Pollack, 40Burton Pollack, 89Carolyn Pollack, 60Cathy E Pollack, 66Connor J Pollack, 34Cris G Pollack, 58

Vincent Pollack Phones & Addresses

  • 55 Vinegar Hill Rd, Gales Ferry, CT 06335 (860) 464-9347
  • Niantic, CT

Work

Position: Financial Professional

Education

Degree: Graduate or professional degree

Publications

Us Patents

Antibodies Directed To Gpnmb And Uses Thereof

View page
US Patent:
20130022597, Jan 24, 2013
Filed:
Jan 20, 2012
Appl. No.:
13/355366
Inventors:
Meina Liang - Fremont CA, US
Orit Foord - Foster City CA, US
Scott Klakamp - Fremont CA, US
Vincent A. Pollack - Gales Ferry CT, US
Luca Rastelli - Guilford CT, US
John Herrmann - Bothell WA, US
Henri Lichenstein - Guilford CT, US
Michael Jeffers - Branford CT, US
William LaRochelle - Madison CT, US
Peter Mezes - Old Lyme CT, US
Andrei Chapoval - Towson MD, US
Cyrus Karkaria - Branford CT, US
Michael Torgov - Middletown CT, US
Juan Davagnino - Madison CT, US
International Classification:
A61K 39/395
C12N 15/13
C40B 30/04
C12N 15/63
C12N 1/21
C12N 5/10
C07K 16/18
A61P 35/00
US Classification:
4241351, 5303879, 5303917, 536 2353, 5303873, 4241391, 4241831, 4353201, 43525233, 435331, 506 9
Abstract:
The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

Method Of Treating Ovarian And Renal Cancer Using Antibodies Against T Cell Immunoglobulin Domain And Mucin Domain 1 (Tim-1) Antigen

View page
US Patent:
20130202527, Aug 8, 2013
Filed:
Apr 15, 2013
Appl. No.:
13/862510
Inventors:
Vincent A. Pollack - Gales Ferry CT, US
John MacDougall - Hamden CT, US
Suresh G. Shenoy - Branford CT, US
Tranci Mansfield - Guilford CT, US
Henri Lichenstein - Guilford CT, US
Michael E. Jeffers - Branford CT, US
William J. LaRochelle - Madison CT, US
Assignee:
Celldex Therapeutics, Inc. - Needham MA
International Classification:
C07K 16/18
C07K 16/42
US Classification:
424 149, 4241721, 4241301, 4241521, 4241411, 4241831, 4241781
Abstract:
The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies for the treatment of cancer (e.g., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Antibodies Directed To Gpnmb And Uses Thereof

View page
US Patent:
20130244255, Sep 19, 2013
Filed:
Feb 7, 2012
Appl. No.:
13/368030
Inventors:
Vincent A. Pollack - Gales Ferry CT, US
William LaRochelle - Madison CT, US
International Classification:
G01N 33/68
US Classification:
435 723, 436501
Abstract:
The present invention relates to antibodies with specificity to GPNMB, and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides biomarkers for evaluating the effects of therapeutic methods and uses of the antibodies with specificity to GPNMB.

Method Of Treating Ovarian And Renal Cancer Using Antibodies Against T Cell Immunoglobulin Domain And Mucin Domain 1 (Tim-1) Antigen

View page
US Patent:
20170267750, Sep 21, 2017
Filed:
Mar 22, 2017
Appl. No.:
15/465994
Inventors:
- Hampton NJ, US
Vincent A. Pollack - Gales Ferry CT, US
John MacDougall - Hamden CT, US
Suresh G. Shenoy - Branford CT, US
Traci Mansfield - Guilford CT, US
Henri Lichenstein - Guilford CT, US
Michael E. Jeffers - Branford CT, US
William J. LaRochelle - Madison CT, US
International Classification:
C07K 16/18
A61K 51/10
B82Y 5/00
C07K 16/28
C07K 16/30
C07K 16/42
G01N 33/574
A61K 39/00
Abstract:
The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies for the treatment of cancer (e.g., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Antibodies Directed To Gpnmb And Uses Thereof

View page
US Patent:
20160311919, Oct 27, 2016
Filed:
Feb 25, 2016
Appl. No.:
15/053204
Inventors:
- Needham MA, US
- Fremont CA, US
Meina Liang - Fremont CA, US
Orit Foord - Foster City CA, US
Scott Klakamp - Fremont CA, US
Kam Fai Tse - Clinton CT, US
Vincent A. Pollack - Gales Ferry CT, US
Luca Rastelli - Guilford CT, US
John Herrmann - Bothell WA, US
Henri Lichenstein - Guilford CT, US
Michael E. Jeffers - Branford CT, US
William J. LaRochelle - Madison CT, US
Gulshan Ara - Harrisburg PA, US
Peter Mezes - Old Lyme CT, US
Andrei Chapoval - Towson MD, US
Cyrus Karkaria - Branford CT, US
Michael Torgov - Middletown CT, US
Juan Davagnino - Madison CT, US
International Classification:
C07K 16/30
C07K 16/28
A61K 47/48
Abstract:
The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

Antibodies Directed To Gpnmb And Uses Thereof

View page
US Patent:
20150044212, Feb 12, 2015
Filed:
Aug 7, 2014
Appl. No.:
14/454179
Inventors:
- Hampton NJ, US
- Fremont CA, US
Meina Liang - Fremont CA, US
Orit Foord - Foster City CA, US
Scott Klakamp - Fremont CA, US
Kam Fai Tse - Clinton CT, US
Vincent A. Pollack - Gales Ferry CT, US
Luca Rastelli - Guilford CT, US
John Herrmann - Bothell WA, US
Henri Lichenstein - Guilford CT, US
Michael E. Jeffers - Branford CT, US
William J. LaRochelle - Madison CT, US
Gulshan Ara - Harrisburg PA, US
Peter Mezes - Old Lyme CT, US
Andrei Chapoval - Towson MD, US
Cyrus Karkaria - Branford CT, US
Michael Torgov - Middletown CT, US
Juan Davagnino - Madison CT, US
International Classification:
C07K 16/30
C07K 16/28
A61K 47/48
US Classification:
4241351, 4241421, 4241831
Abstract:
The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.
Control profile
Vincent A Pollack from Gales Ferry, CTDeceased Get Report